Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma

Giuseppe Badalamenti, Filippo Ceccato, Vittoria Basile, Soraya Puglisi, Barbara Altieri, Giorgio Arnaldi, Francesco Ferraù, Paola Berchialla, Laura Saba, Marco Russo, Antonio Stigliano, Carla Scaroni, Anna Calabrese, Silvia Della Casa, Alessandra Quirino, Marco Russo, Letizia Canu, Paola Perotti, Massimo Torlontano, Carla ScaroniPaola Loli, Rosario Pivonello, Massimo Terzolo, Maria Cristina De Martino

Risultato della ricerca: Articlepeer review

7 Citazioni (Scopus)

Abstract

Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding the impact of plasma mitotane levels on patient outcome. To address this question, we retrospectively analyzed patients with advanced ACC treated with mitotane for ≥3 months, with ≥3 measurements of plasma mitotane reported in the Lysosafe Online® database (HRA Pharma, France), followed at 12 tertiary centers in Italy from 2005 to 2017. We identified 80 patients, initially treated with mitotane alone (56.2%) or plus chemotherapy (43.8%). The preference toward combination therapy was given to de novo stage IV ACC and younger patients. After the first line of treatment, 25% of valid cases experienced clinical benefit (14.5% objective response, 10.5% stabilization of disease) and 75% progression, without differences between the groups of treatment. Patients with progression had a lower time in the target range (TTR) of plasma mitotane and an unfavorable outcome. Death occurred in 76.2% of cases and multivariate analysis showed that clinical benefit after first treatment and longer TTR were favorable predictors of overall survival (OS). In conclusion, the present findings support the importance of mitotane monitoring and strengthen the concept of a therapeutic window for mitotane.
Lingua originaleEnglish
pagine (da-a)740-
Numero di pagine13
RivistaCancers
Volume12
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma'. Insieme formano una fingerprint unica.

Cita questo